PARP1 and ovarian carcinoma: PARP inhibitors are now used as a maintenance therapy for patients with BRCAMUT epithelial ovarian cancer and as a treatment of relapsed BRCAMUT ovarian cancer in patients who have been treated with two or more chemotherapies before [32,33].